Dividend Giants Eye Bold Price Targets in 2027

Pfizer, Chevron, and AbbVie have been strong performers in 2026, with year-to-date gains of 19.3%, 38.76%, and 19.16% respectively.

The three dividend giants are expected to continue their upward trend into 2027, with price targets set at $35 for Pfizer, $250 for Chevron, and $325 for AbbVie.

Pfizer's path to $35 is driven by its obesity and oncology pipeline, including Metsera's GLP-1 targeting a $150 billion market and Padcev growth over 20%.

Chevron's case for reaching $250 relies on the success of Guyana, Hess synergies, and AI-powered projects like Microsoft's Project Kilby.

AbbVie's $325 target hinges on the performance of Skyrizi and Rinvoq, with management raising full-year EPS to $13.87 to $14.07.